197 completed, 130 recruiting, 90 terminated, 75 active not recruiting. 284 Phase 2, 206 Phase 1, 48 Phase 3, 40 Not applicable, 13 Early Phase 1.
Follow Carcinoma, Transitional Cell: new trials by email Literature Review of Carcinoma, Transitional Cell trials Research Report on Carcinoma, Transitional Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma enfortumab vedotin and pembrolizumab (EV/P) - Urothelial Carcinoma (UC) | Phase 2 | Not yet recruiting | University of Florida | 39 | 2026-12-01 | 2026-09-14 |
| N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer Nogapendekin Alfa Inbakicept (NAI), enfortumab vedotin (EV), Pembrolizumab - Metastatic Urothelial Carcinoma, Urothelial Carcinoma | Phase 1 | Not yet recruiting | ImmunityBio, Inc. | 18 | 2026-12-01 | 2026-09-24 |
| Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study Toripalimab, Gemcitabine (GEM), Mitomycin C (MMC) - Urinary Bladder Neoplasms, Carcinoma, Transitional Cell | Phase 2 | Not yet recruiting | First Affiliated Hospital of Wenzhou Medical University | 106 | 2026-12-01 | 2026-09-08 |
| Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 50 | 2026-12-01 | 2026-09-17 |
| Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic STRO-006, Pembrolizumab - Head & Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer | Phase 1 | Not yet recruiting | Sutro Biopharma, Inc. | 285 | 2026-09-14 | 2026-09-08 |
| A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma Ivonescimab Dose 1, enfortumab vedotin (EV), Pembrolizumab - Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma (UC) | Phase 2 / Phase 3 | Recruiting | Summit Therapeutics | 800 | 2026-09-10 | 2026-09-11 |
| Prospective Collection And Molecular Analysis Of Biospecimens And Clinical Data From Patients With Urothelial Carcinoma And Related Malignancies Of The Urinary Tract biospecimen Collection - Urothelial Carcinoma | Recruiting | M.D. Anderson Cancer Center | 50000 | 2026-09-10 | 2026-10-05 | |
| Bladder Preservation or Cystectomy for MIBC Gemzar, Cisplatin, Adrucil - Muscle-Invasive Bladder Carcinoma, Bladder Cancer | Early Phase 1 | Active not recruiting | Dana-Farber Cancer Institute | 20 | 2026-09-02 | 2026-09-15 |
| Study of Peripheral Neuropathy in Patients With Advanced Urothelial Cancer Treated With Enfortumab Vedotin and Pembrolizumab With Supportive Neuridase (ENDEAVOR) enfortumab vedotin (EV), PEMBROLIZUMAB (alone or when added to a regimen above), Neuridase - Urothelial Carcinoma (UC), Peripheral Nerve Disease | Not applicable | Not yet recruiting | University of Florence | 40 | 2026-09-01 | 2026-06-08 |
| A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors BL-M09D1 - Urothelial Carcinoma (UC), Solid Tumors | Phase 2 | Not yet recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 42 | 2026-09-01 | 2026-09-23 |
| RESTORE-BLADDER (REgistry on STrategies for Organ pREservation in Muscle-invasive BLADDER Cancer) None. Registry. - Muscle Invasive Bladder Cancer (MIBC) | Not yet recruiting | Heinrich-Heine University, Duesseldorf | 100 | 2026-09-01 | 2026-08-04 | |
| FAPI PET Imaging - An Exploratory Study [18F]FAPI-74 PET/CT - Thyroid Pathology, Head and Neck Cancer (H&N) | Phase 1 / Phase 2 | Not yet recruiting | Martin Huellner | 770 | 2026-08-01 | 2026-07-15 |
| Trop2-Targeted NIR-II Fluorescent Probe for Identifying Bladder Cancer in Ex Vivo Bladder Samples TTP-ICG fluorescent probe - Bladder Cancer (BC), Urothelial Carcinoma (UC) | Phase 2 | Recruiting | Yunnan Cancer Hospital | 30 | 2026-08-01 | 2026-09-30 |
| A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors ARV-6723, Pembrolizumab, SOC - Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | Arvinas Inc. | 499 | 2026-07-29 | 2026-10-13 |
| DBC-664 in Adult Patients With Solid Tumors DBC-664 - Malignant Germ Cell Tumor, Lung Adenocarcinoma | Phase 1 | Recruiting | Duboce Biopharmaceuticals, Inc. | 210 | 2026-07-17 | 2026-09-29 |
| An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC Dato-DXd, Rilvegostomig, Durvalumab - High-risk Muscle Invasive Urothelial Carcinoma | Phase 3 | Recruiting | AstraZeneca | 915 | 2026-07-16 | 2026-07-22 |
| A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors HLX18, OPDIVO® - Esophageal and/or Cardia Cancer, Melanoma | Phase 1 | Recruiting | Shanghai Henlius Biotech | 174 | 2026-07-15 | 2026-07-27 |
| Sacituzumab Tirumotecan vs MMAE-ADCs in Advanced Urothelial Carcinoma (FUSCC-SPARE-UC-01) Sacituzumab Tirumotecan, MMAE-based ADC, Sacituzumab Tirumotecan (Observational Cohort) - Bladder Cancer, Metastatic Urothelial Carcinoma | Phase 2 | Not yet recruiting | Fudan University | 75 | 2026-07-15 | 2026-06-23 |
| Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer Disitamab vedotin, Toripalimab, Sitagliptin - Bladder Urothelial Carcinoma, Bladder Cancer | Phase 2 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 80 | 2026-07-01 | 2026-07-21 |
| A Phase II Study of AK146D1 Mono or Combined With AK112 in Advanced Urothelial Carcinoma AK146D1 for injection, AK112 Injection - Urothelial Carcinoma (UC) | Phase 2 | Not yet recruiting | Akeso | 132 | 2026-06-22 | 2026-06-09 |
Showing 20 of 619. Sign in to see all of them.
Urinary Bladder Neoplasms (204) · Carcinoma, Non-Small-Cell Lung (116) · Carcinoma, Renal Cell (96) · Melanoma (81) · Squamous Cell Carcinoma of Head and Neck (68) · Colorectal Neoplasms (62) · Neoplasm Metastasis (56) · Uterine Cervical Neoplasms (56) · Stomach Neoplasms (55) · Ovarian Neoplasms (52) · Carcinoma, Hepatocellular (50) · Triple Negative Breast Neoplasms (49) · Neoplasms (48) · Breast Neoplasms (44)
Neoplasms, Glandular and Epithelial (618) · Neoplasms by Histologic Type (617) · Carcinoma (603) · Neoplasms (571) · Neoplasms by Site (390) · Urogenital Diseases (355) · Female Urogenital Diseases and Pregnancy Complications (353) · Female Urogenital Diseases (352) · Urogenital Neoplasms (339) · Male Urogenital Diseases (329) · Urologic Diseases (310) · Urologic Neoplasms (291) · Urinary Bladder Diseases (200) · Thoracic Neoplasms (141) · Respiratory Tract Diseases (140)
pembrolizumab (98) · Gemcitabine (59) · Nivolumab (51) · Cisplatin (42) · atezolizumab (37) · Carboplatin (31) · enfortumab vedotin (30) · avelumab (29) · Docetaxel (24) · Magnetic Resonance Spectroscopy (18) · Mitomycin (18) · Ipilimumab (17) · Paclitaxel (16) · Specimen Handling (14) · durvalumab (12)
National Cancer Institute (NCI) (23) · M.D. Anderson Cancer Center (14) · Memorial Sloan Kettering Cancer Center (11) · Pfizer (10) · UroGen Pharma Ltd. (10) · National Taiwan University Hospital (9) · Bristol-Myers Squibb (8) · Fox Chase Cancer Center (8) · Hoffmann-La Roche (8) · Incyte Corporation (8) · Eli Lilly and Company (7) · H. Lee Moffitt Cancer Center and Research Institute (7) · Astellas Pharma Global Development, Inc. (6) · Changhai Hospital (6) · Dana-Farber Cancer Institute (5)
United States (350) · China (88) · Spain (79) · France (70) · Canada (61) · Italy (60) · United Kingdom (52) · South Korea (48) · Germany (45) · Australia (42) · Belgium (38) · Japan (38) · Taiwan (38) · Netherlands (37) · Israel (29)
Andrea B Apolo, M.D. (5) · Matthew Galsky, M.D. (4) · Tony Lough, PhD (4) · Andrea Necchi, MD (3) · Samuel Funt, MD (3) · Sarmad Sadeghi, MD (3) · Abhishek Tripathi, MD (2)
PMID 11001674, PMID 29415874, PMID 30807645, PMID 32945632, PMID 33037018, PMID 37988648, PMID 38573872, PMID 41144872, PMID 42580817, PMID 11352955, PMID 11600601, PMID 11844814, PMID 12586807, PMID 12771730, PMID 12944571, PMID 15939524, PMID 16034041, PMID 1607913, PMID 16330205, PMID 16849761, PMID 18024869, PMID 18685414, PMID 18833002, PMID 19171491, PMID 19389012, PMID 19687335, PMID 19913890, PMID 21502557, PMID 22012004, PMID 22847809, PMID 22923433, PMID 23460707, PMID 23510863, PMID 23551593, PMID 23563166, PMID 23706985, PMID 23835707, PMID 23954585, PMID 24055428, PMID 24089446, PMID 24373477, PMID 24472710, PMID 24566706, PMID 24669010, PMID 24821881, PMID 24821883, PMID 25257030, PMID 25286009, PMID 25427282, PMID 25429526
2023 (11), 2017 (9), 2016 (8), 2018 (6), 2019 (6), 2025 (6), 2014 (4), U10CA180821 (4), 2015 (3), P30CA014089 (2), P30CA060553 (2), P30CA138292 (2), U01CA062505 (2), U10CA180888 (2), UM1CA186644 (2)